<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Amiodarone: Clinical uses
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Amiodarone: Clinical uses
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Amiodarone: Clinical uses
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elsa-Grace Giardina, MD, MS, FACC, FACP, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rod Passman, MD, MSCE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Samuel Lévy, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Zimetbaum, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H27142111">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is an iodinated benzofuran derivative that was synthesized and tested as an antianginal agent in the 1960s but was later discovered to have antiarrhythmic properties. Amiodarone is widely prescribed, largely due to its efficacy in the management of both supraventricular and ventricular arrhythmias. In addition to the superior efficacy compared with most other antiarrhythmic drugs, amiodarone has very little negative inotropic activity and a low rate of ventricular proarrhythmia, making it advantageous for use in patients with heart failure [
         <a href="#rid1">
          1
         </a>
         ]. Despite these advantages, the use of amiodarone is associated with a relatively high incidence of side effects, making it a complicated drug to use safely.
        </p>
        <p>
         This topic will review the electrophysiologic properties of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , clinical indications, and dosing recommendations for oral and intravenous amiodarone. The side effects of amiodarone are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7834.html" rel="external">
          "Amiodarone and thyroid dysfunction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27142119">
         <span class="h1">
          PHARMACOKINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Slow and wide distribution of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         to tissue (fat, muscle, highly perfused organs) results in a requirement of long loading periods in an effort to accelerate the onset of drug activity. Oral amiodarone is markedly lipophilic, resulting in a very large volume of distribution (average approximately 66 L/kg) and a prolonged time to reach stable plasma levels [
         <a href="#rid1">
          1
         </a>
         ]. It is incompletely absorbed (approximately 30 to 70 percent) after oral administration and is taken up very extensively by tissue, with marked interindividual variation [
         <a href="#rid2">
          2
         </a>
         ]. Because of these characteristics, even with loading, arrhythmia recurrence during the first months of therapy does not necessarily predict long-term efficacy. Conversely, intravenous (IV) amiodarone begins to act within one hour, with rapid onset of action within minutes following an IV bolus.
        </p>
        <p>
         Estimates of the elimination half-life of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         vary, depending on how the half-life has been measured and the route of amiodarone administration.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After long-term oral therapy,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         has a true elimination half-life between 60 and 142 days [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The relatively short half-life for disappearance of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         from plasma after a single-dose or short-term IV administration is likely a measure of drug redistribution from vascular space into tissue and not true body elimination.
        </p>
        <p>
        </p>
        <p>
         There is little correlation between the plasma concentration of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or its major active metabolite, desethylamiodarone, and drug efficacy or toxicity [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H27142126">
         <span class="h1">
          ELECTROPHYSIOLOGIC PROPERTIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The electrophysiologic properties of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         are complex and incompletely understood. Though classified as a Vaughan-Williams class III antiarrhythmic agent due to its inhibition of outward potassium channels, the drug also has class I sodium channel blocking effects, class II antiadrenergic effects, and class IV calcium channel blocking effects  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 1
         </a>
         ). The oral and intravenous (IV) forms of amiodarone have important electrophysiologic differences that have an impact on their clinical use  (
         <a class="graphic graphic_table graphicRef79689" href="/z/d/graphic/79689.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H27142133">
         <span class="h2">
          Oral amiodarone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is classified as a class III antiarrhythmic agent since it prolongs the duration of the action potential and the refractory period of both atrial and ventricular tissue  (
         <a class="graphic graphic_figure graphicRef64133" href="/z/d/graphic/64133.html" rel="external">
          figure 1
         </a>
         ). This effect is primarily mediated by blockade of the rapid component of the delayed rectifier current (IKr) that is responsible for phase 3 repolarization of the action potential  (
         <a class="graphic graphic_figure graphicRef70771" href="/z/d/graphic/70771.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/895.html" rel="external">
          "Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"
         </a>
         .)
        </p>
        <p>
         Like other class III agents (
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         ),
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         prolongs the QT interval. However, by contrast to most other class III agents, amiodarone has very little proarrhythmic activity. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring", section on 'Adverse cardiac effects'
         </a>
         .)
        </p>
        <p>
         Oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         has several other effects that may contribute to its therapeutic efficacy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It inhibits inactivated (phase 0) sodium channels, an effect that is primarily seen at rapid heart rates
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It has some class II antiarrhythmic drug activity, inhibiting sympathetic activity, primarily by causing noncompetitive beta receptor blockade
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It also has some class IV antiarrhythmic drug activity by blocking L-type (slow) calcium channels
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6004678">
         <span class="h2">
          Intravenous amiodarone
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         has a number of important electrophysiologic differences from chronically administered oral amiodarone [
         <a href="#rid4">
          4,5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         produces a much smaller increase in the action potential duration in atrial and ventricular myocardium and a minimal increase in the atrial and ventricular refractory periods. As a result, there is little or no increase in QRS duration or the QT interval, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         has little effect on sinus cycle length. It has vasodilator activity that triggers an increase in sympathetic activity, and as a result, there is little or no slowing of the sinus rate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         may have more potent and more rapid antiadrenergic activity.
        </p>
        <p>
        </p>
        <p>
         Like oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , IV amiodarone inhibits inactivated sodium channels, though to a lesser degree than the oral form [
         <a href="#rid4">
          4
         </a>
         ]. This property may account for the efficacy of the agent in the suppression of ventricular tachyarrhythmias [
         <a href="#rid6">
          6
         </a>
         ]. IV amiodarone also prolongs atrioventricular (AV) nodal conduction and refractoriness and may be effective in slowing the ventricular rate in critically ill patients with atrial tachyarrhythmias [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6004686">
         <span class="h2">
          Effects on the ECG
         </span>
         <span class="headingEndMark">
          —
         </span>
         The multiple actions of chronically administered oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         therapy can produce a variety of changes in the electrocardiogram (ECG). These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Slowing of the sinus rate. Both calcium channel blockade and beta blockade may contribute to this effect, which can lead to sinus bradycardia [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolongation of the PR interval and the AV nodal refractory period. Thus, AV conduction block may occur, an effect that may also be related to calcium channel blockade since the AV node is a "slow response" tissue that relies on an inward calcium current for depolarization. (See
         <a class="medical medical_review" href="/z/d/html/895.html" rel="external">
          "Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs", section on 'Action potential in slow response tissues'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Widening of the QRS complex (typically less than 10 percent), as conduction is slowed in ventricular muscle by the blocking effect on the inactivated sodium channel, thereby slowing phase 0 depolarization  (
         <a class="graphic graphic_figure graphicRef64133" href="/z/d/graphic/64133.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/895.html" rel="external">
          "Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolongation of the QT interval (typically less than 10 percent) due to blockade of IKr, the delayed rectifier potassium current that is responsible for phase 3 depolarization of the action potential  (
         <a class="graphic graphic_figure graphicRef64133" href="/z/d/graphic/64133.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid8">
          8,9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring", section on 'Adverse cardiac effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6004209">
         <span class="h1">
          ORAL AMIODARONE FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         can be used to treat most types of atrial arrhythmias but is used primarily to maintain normal sinus rhythm in patients with atrial fibrillation (AF). However, oral amiodarone is not FDA approved in the United States for rhythm control in AF, despite common usage for this indication. It is commonly used for several reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is the most effective medical therapy available for maintaining sinus rhythm
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is a low risk of ventricular proarrhythmia based on the electrophysiologic properties of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         does not increase mortality in heart failure patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapy can be easily initiated on an outpatient basis
        </p>
        <p>
        </p>
        <p>
         In addition, if AF recurs,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         usually slows the ventricular response at rest and with exercise. It also may reduce symptoms associated with rapid ventricular response to AF, though amiodarone is not recommended solely as a rate-controlling agent. (See
         <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Amiodarone'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         can be used to treat other atrial arrhythmias such as atrial flutter or atrial tachycardia, but the availability of other antiarrhythmic drugs with lower toxicity rates, and the high success rates of ablative approaches to atrial flutter or atrial tachycardia, often favors these alternatives. The major limiting factor in the use of oral amiodarone for the treatment of AF and other atrial arrhythmias is long-term organ toxicity (eg, thyroid, lung, etc)  (
         <a class="graphic graphic_table graphicRef126072" href="/z/d/graphic/126072.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17047167">
         <span class="h2">
          Prevention of recurrent paroxysmal atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to pursue a strategy of rhythm control in any patient with AF is complex and depends on:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence or absence of symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potential adverse effects of persistent AF (ie, uncontrolled ventricular rate)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse effects of alternative therapies for AF
        </p>
        <p>
        </p>
        <p>
         The choice of which antiarrhythmic drug to use for paroxysmal AF is also complex and based on a variety of factors, most notably the presence and type of structural heart disease. Unlike many other antiarrhythmic drugs,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         has a low risk of ventricular proarrhythmia and does not increase mortality when administered to patients with coronary disease, left ventricular (LV) hypertrophy, LV dysfunction, or congestive heart failure.
        </p>
        <p>
         While there is no universally accepted dosing regimen, oral loading doses of 400 to 1200 mg/day in divided doses (up to a total loading dose of 6 to 10 grams) can be used  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ]. Gastrointestinal side effects may limit loading doses. The usual maintenance dose should be the lowest effective dose, which for AF is usually 200 mg daily but can sometimes be as low as 100 mg daily. Doses up to 400 mg/day may also be used but are not recommended for routine maintenance given the higher risk of adverse events. (See
         <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">
          "Management of atrial fibrillation: Rhythm control versus rate control"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17047227">
         <span class="h2">
          Pharmacologic cardioversion of atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is not a first-line therapy for pharmacologic cardioversion given its limited efficacy and long onset of action. If amiodarone is used in this setting, American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines recommend oral loading and maintenance doses to be the same as those described for amiodarone use to prevent recurrence and maintain sinus rhythm in patients with paroxysmal AF. (See
         <a class="local">
          'Prevention of recurrent paroxysmal atrial fibrillation'
         </a>
         above.)
        </p>
        <p>
         Oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         can result in pharmacologic cardioversion of AF in approximately 25 percent of patients with high ventricular rates from either acute or recent-onset AF [
         <a href="#rid10">
          10-12
         </a>
         ]. Because of the potential for cardioversion following administration of amiodarone, standard precautions need to be considered to prevent thromboembolic events. (See
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         and other pharmacologic agents for cardioversion are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion", section on 'Pharmacologic cardioversion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17047234">
         <span class="h2">
          Pretreatment before elective cardioversion or catheter ablation for persistent atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who did not remain in sinus rhythm following cardioversion or in patients at high risk for recurrent AF after planned cardioversion, we often pretreat with an antiarrhythmic drug, including
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         [
         <a href="#rid13">
          13
         </a>
         ]. Given the prolonged half-life of oral amiodarone, the loading time is extended, so the drug should be started two to six weeks prior to elective cardioversion to reduce the risk of recurrence. Dosing regimens vary  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ) but generally aim for an oral load of 6 to 10 grams over a period of two to six weeks prior to cardioversion, with a decrease in dose to maintenance levels (usually 100 to 200 mg daily) following cardioversion or shortly thereafter. Given the unique pharmacologic properties of amiodarone, AF recurrences in the first two to three months following cardioversion do not necessarily predict long-term failure of the drug. (See
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion", section on 'Preprocedural antiarrhythmic drugs'
         </a>
         .)
        </p>
        <p>
         Oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         has also been investigated in patients undergoing catheter ablation for persistent AF.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the AMIO-CAT trial, in which 212 patients undergoing AF ablation were randomized to begin therapy with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or placebo for eight weeks following catheter ablation, there was a nonsignificant trend toward fewer recurrences of AF in the amiodarone group (39 versus 48 percent), but significantly fewer patients receiving amiodarone required hospitalization or cardioversion for recurrent AF [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the SPECULATE trial, in which 112 patients with long-standing persistent AF were randomized to discontinuation of chronic
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         therapy four months prior to ablation or continuation of therapy and then followed for an average of 32 months, significantly more patients who continued amiodarone had successful termination of AF at the time of ablation (79 versus 57 percent); however, late AF recurrence was significantly greater in the group who continued amiodarone [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Further investigation is needed to determine the optimal role for
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in patients undergoing AF ablation.
        </p>
        <p class="headingAnchor" id="H17047241">
         <span class="h2">
          Prophylaxis against atrial fibrillation following cardiac surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         lowers the incidence of postoperative AF in patients undergoing cardiac surgery [
         <a href="#rid10">
          10
         </a>
         ]. Various dosing regimens for oral amiodarone have been used in clinical trials [
         <a href="#rid16">
          16,17
         </a>
         ]. In general, however, we recommend beta blockers rather than amiodarone; however, for patients who cannot take beta blockers, amiodarone may be used. The approach to prevention of AF following cardiac surgery is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">
          "Atrial fibrillation and flutter after cardiac surgery", section on 'Amiodarone'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6004252">
         <span class="h1">
          INTRAVENOUS AMIODARONE FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous (IV)
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is primarily used for the treatment of atrial arrhythmias in two settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restoration and maintenance of sinus rhythm in critically ill patients with hemodynamically unstable atrial fibrillation (AF).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rate control in critically ill patients with AF with rapid ventricular response in whom the tachycardia is contributing to hemodynamic compromise.
        </p>
        <p>
        </p>
        <p>
         The administration of IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         requires attention to a specific dosing schedule to minimize side effects, which are largely different from those seen with chronic oral therapy. In addition, there is substantial interindividual variability in response time; as a result, careful patient observation and dose adjustment are recommended as necessary.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         should be mixed in a 5 percent dextrose solution and the amiodarone concentration kept below 2 mg/mL if given through a peripheral vein to minimize the development of local phlebitis. Higher drug concentrations must be delivered through an indwelling catheter in a central vein.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is physically incompatible with a number of drugs, including heparin, which should not be given in the same solution. (See
         <a class="local">
          'Side effects with IV administration'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H6004275">
         <span class="h2">
          Restoration and maintenance of sinus rhythm in critically ill patients with hemodynamically unstable atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         AF is common in critically ill patients and may contribute to hemodynamic instability. IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         can be used in this situation but has not been sufficiently studied in this population to allow for specific recommendations. When administered  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ), an initial IV loading dose of 150 mg is given over a minimum of 10 minutes. More rapid infusion increases the risk of hypotension. The loading dose should be followed by a continuous infusion of 1 mg/minute for six hours and 0.5 mg/minute thereafter [
         <a href="#rid1">
          1
         </a>
         ]. This regimen delivers 1050 mg of amiodarone in the first 24 hours.
        </p>
        <p>
         In general, the reported efficacy of IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in restoring and maintaining sinus rhythm is inconsistent, though professional society guidelines list IV amiodarone as an option for pharmacologic cardioversion [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion", section on 'Indications'
         </a>
         .)
        </p>
        <p>
         Several meta-analyses have been published evaluating the efficacy of IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in restoration of normal sinus rhythm in critically ill patients [
         <a href="#rid18">
          18-20
         </a>
         ]. The meta-analyses have included studies with widely varying methodologies, leading to some conflicting results.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The largest meta-analysis included studies comparing
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         with other antiarrhythmic drugs or placebo [
         <a href="#rid19">
          19
         </a>
         ]. IV amiodarone was as efficacious as other antiarrhythmic drugs and more effective than placebo, but amiodarone was associated with a higher rate of adverse events compared with placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another meta-analysis, which included only studies comparing
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         with placebo or class Ic antiarrhythmic drugs, determined that conversion from AF to sinus rhythm was greater at 8 and 24 hours, but not at one or two hours [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Conversion rates from AF to sinus rhythm following IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         are higher when the bolus (3 to 7 mg/kg) is followed by continuous infusion (900 to 3000 mg daily) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6004289">
         <span class="h2">
          Ventricular rate control in critically ill patients with atrial fibrillation and rapid ventricular response
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         may be used as a rate-controlling agent in critically ill individuals with hemodynamically destabilizing AF who cannot be maintained in sinus rhythm and in whom standard rate-controlling therapies have been either unsuccessful or are contraindicated due to hypotension. An initial IV loading dose of 150 mg is given over a minimum of 10 minutes  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ). More rapid infusion increases the risk of hypotension. The loading dose should be followed by a continuous infusion of 1 mg/minute for six hours and 0.5 mg/minute thereafter [
         <a href="#rid1">
          1
         </a>
         ]. This regimen delivers 1050 mg of amiodarone in the first 24 hours. Repeated 150 mg boluses can be given over 10 to 30 minutes, but no more than six to eight additional boluses should be administered in any 24-hour period.
        </p>
        <p>
         AF with rapid ventricular response may contribute to hemodynamic compromise. Furthermore, ventricular rates &gt;120 beats/minute for prolonged periods of time may contribute to left ventricular dysfunction. In a retrospective study, intensive care unit patients with hemodynamically destabilizing AF or atrial flutter resistant to conventional therapy experienced a significant 37 beat/minute decrease in ventricular rate and an increase in systolic blood pressure of 24 mmHg with no associated adverse effects [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         may also be used for rate control in patients with congestive heart failure [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6004619">
         <span class="h1">
          AMIODARONE FOR VENTRICULAR ARRHYTHMIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is useful in a variety of ventricular arrhythmias including ventricular premature beats (VPBs), nonsustained ventricular tachycardia (VT), and sustained VT or ventricular fibrillation (VF). Most commonly, amiodarone is used for the secondary prevention of recurrent ventricular arrhythmias in patients with an implantable cardioverter-defibrillator (ICD) to reduce the frequency of ICD shocks. Typically, a beta blocker is co-administered with amiodarone.
        </p>
        <p class="headingAnchor" id="H6004627">
         <span class="h2">
          Treatment of ventricular arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         suppresses VPBs and episodes of nonsustained VT. This is clearly demonstrated in several of the primary prevention trials of amiodarone in post-myocardial infarction (MI) and congestive heart failure patients in whom baseline and follow-up 24-hour ambulatory ECGs were performed. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Canadian
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         Myocardial Infarction Arrhythmia Trial (CAMIAT) pilot study enrolled patients with frequent or repetitive asymptomatic ventricular premature depolarizations (VPDs) [
         <a href="#rid21">
          21
         </a>
         ]. When compared with placebo, patients receiving amiodarone had much greater suppression of VPDs and nonsustained VT (86 compared with 50 percent of placebo patients).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The CHF-STAT trial compared
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         versus placebo in patients with heart failure, left ventricular (LV) ejection fraction of 40 percent or less, and frequent VPBs (more than 10/hour) [
         <a href="#rid22">
          22
         </a>
         ]. Following two weeks of treatment, significantly fewer patients on amiodarone had VT on Holter monitor (33 versus 76 percent). Despite the reduction in ventricular arrhythmias and ectopy, amiodarone did not reduce mortality.
        </p>
        <p>
        </p>
        <p>
         Additional trials are reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/946.html" rel="external">
          "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is also one of the few antiarrhythmic drugs that does not increase mortality when given to patients with moderate to severe LV dysfunction. The apparent efficacy and safety of amiodarone for the treatment of ventricular tachyarrhythmias in patients with structural heart disease have led to several studies evaluating the impact of amiodarone on survival in patients at high risk of arrhythmic death.
        </p>
        <p class="headingAnchor" id="H6004642">
         <span class="h2">
          Primary prevention of sudden cardiac death
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         for primary prevention of sudden cardiac death (SCD) is generally considered only for patients with LV dysfunction who are not candidates for, or refuse to have, ICD implantation [
         <a href="#rid23">
          23
         </a>
         ]. When administered  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ), the recommended loading dose for the prevention of ventricular arrhythmias is 400 to 1200 mg/day (usually in divided doses) for a total of 6 to 10 grams [
         <a href="#rid1">
          1
         </a>
         ]. Higher loading dose regimens have been evaluated but do not appear to provide greater efficacy. Maintenance doses range from 200 to 400 mg/day, with the lower doses carrying less risk of adverse side effects.
        </p>
        <p>
         Ventricular arrhythmias are responsible for a large proportion of SCDs, especially in those individuals with underlying structural heart disease. The ability of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         to suppress ventricular arrhythmias led to several trials designed to assess its effect on patients deemed high risk for ventricular arrhythmias either because they have already survived a sustained ventricular tachyarrhythmia or were believed to be at high risk of developing such arrhythmias due to the presence of LV dysfunction.
        </p>
        <p>
         Earlier studies comparing
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         with standard medical therapy generally enrolled patients with either recent MI or congestive heart failure [
         <a href="#rid2">
          2
         </a>
         ]. A 2015 Cochrane systematic review and meta-analysis (based on low to moderate quality evidence) concluded that, compared with placebo or no intervention, amiodarone reduced SCD (risk ratio [RR] 0.76, 95% CI 0.66-0.88), total cardiac death (RR 0.86, 95% CI 0.77-0.96), and all-cause mortality (RR 0.88, 95% CI 0.78-1.00) [
         <a href="#rid24">
          24
         </a>
         ]. In trials comparing amiodarone with ICD therapy, ICD therapy was superior in the primary prevention of SCD [
         <a href="#rid25">
          25,26
         </a>
         ]. Because of this, amiodarone for primary prevention of SCD is rarely used without concurrent use of an ICD. (See
         <a class="medical medical_review" href="/z/d/html/946.html" rel="external">
          "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">
          "Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6004670">
         <span class="h2">
          Secondary prevention of sudden cardiac death
         </span>
         <span class="headingEndMark">
          —
         </span>
         In view of the superiority of ICD compared with antiarrhythmic drugs, including
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , for the secondary prevention of SCD, amiodarone should not be used alone for secondary prevention except in those who do not meet ICD criteria, or in those who meet criteria but cannot receive a device or refuse device implantation. When administered  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ), the recommended loading dose for the prevention of ventricular arrhythmias is 400 to 1200 mg/day (usually in divided doses) for a total of 6 to 10 grams [
         <a href="#rid1">
          1
         </a>
         ]. Higher loading dose regimens have been evaluated but do not appear to provide greater efficacy. Maintenance doses range from 200 to 400 mg/day, with the lower doses carrying less risk of adverse side effects.
        </p>
        <p>
         Survivors of SCD due to arrhythmia carry a high risk of recurrence. With the possible exception of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , attempts to significantly reduce SCD rates by using antiarrhythmic drugs have yielded disappointing results, most likely related to the proarrhythmic effects of many antiarrhythmic drugs. The recognition of the limitations of antiarrhythmic drugs for secondary prevention was paralleled by the development of smaller, transvenous ICDs with tiered therapies, bradycardia pacing, and success rates of &gt;95 percent in terminating VT and VF.
        </p>
        <p>
         Several randomized trials and meta-analyses have compared ICDs with antiarrhythmic drugs for secondary prevention of SCD in patients with resuscitated VF, sustained VT with syncope, or sustained VT with ejection fraction ≤40 percent, and evidence of hemodynamic compromise. All showed superior efficacy of ICD compared with antiarrhythmic drugs. (See
         <a class="medical medical_review" href="/z/d/html/946.html" rel="external">
          "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H907869">
         <span class="h2">
          Prevention of ventricular arrhythmias in patients with ICDs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Shocks delivered by an ICD, especially when repetitive, can be painful and impact quality of life [
         <a href="#rid27">
          27
         </a>
         ].
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         may be used to decrease the risk of ICD shocks. When administered  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ), the recommended loading dose for the prevention of ICD shocks is 400 to 1200 mg/day (usually in divided doses) for a total of 6 to 10 grams [
         <a href="#rid23">
          23,28
         </a>
         ]. Maintenance doses range from 200 to 400 mg/day, with the lower doses carrying less risk of adverse side effects.
        </p>
        <p>
         The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Study evaluated
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         plus beta blocker,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         alone, and beta blocker alone for the prevention of ICD shocks in 412 patients [
         <a href="#rid29">
          29
         </a>
         ]. Amiodarone plus beta blocker significantly reduced the risk of shock compared with beta blocker alone (hazard ratio [HR] 0.27, 95% CI 0.14-0.52) or sotalol alone (HR 0.43, 95% CI 0.22-0.85). In the SURVIVE-VT trial, patients with ischemic cardiomyopathy and appropriate ICD shocks who were randomly assigned antiarrhythmic drugs, including amiodarone, were more likely to experience the composite endpoint (including cardiovascular death, appropriate ICD shock, heart failure hospitalization, or severe treatment-related complications), compared with those treated with ablation (HR 0.52, 95%CI 0.30-0.90). (See
         <a class="medical medical_review" href="/z/d/html/972.html" rel="external">
          "Pharmacologic therapy in survivors of sudden cardiac arrest", section on 'Antiarrhythmic drugs'
         </a>
         .)
        </p>
        <p>
         When using
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in patients with ICDs, reassessment of defibrillation threshold may be necessary in those individuals with marginally acceptable defibrillation threshold prior to drug initiation [
         <a href="#rid30">
          30
         </a>
         ]. Additionally, care must be taken in device programming as amiodarone may slow the rate of VT such that the cycle length of spontaneous VT falls outside of the programmed limits (heart rate or cycle length) for detection of VT. (See
         <a class="medical medical_review" href="/z/d/html/989.html" rel="external">
          "Cardiac implantable electronic devices: Long-term complications", section on 'Increased defibrillation threshold'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H907921">
         <span class="h2">
          IV amiodarone for the treatment of electrical storm and incessant ventricular tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in the treatment of electrical storm and incessant VT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1058.html" rel="external">
          "Electrical storm and incessant ventricular tachycardia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H907928">
         <span class="h2">
          IV amiodarone during resuscitation from cardiac arrest
         </span>
         <span class="headingEndMark">
          —
         </span>
         The administration of IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         as part of the advanced cardiac life support protocol for resuscitation of cardiac arrest is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6004579">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H502091829">
         <span class="h2">
          Side effects with IV administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         A major problem noted with the intravenous (IV) preparation is hypotension, which occurs in as many as 26 percent of patients and has been attributed to faster loading rates as well as the solvents used in the preparation [
         <a href="#rid6">
          6,31
         </a>
         ]. Hypotension does not appear to occur with a preparation of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         that employs an aqueous base [
         <a href="#rid32">
          32
         </a>
         ]. Patients who develop hypotension may benefit from a decrease in the infusion rate, while additional IV boluses may be beneficial in patients with recurrent arrhythmias during the early phase of therapy [
         <a href="#rid1">
          1,7
         </a>
         ].
        </p>
        <p>
         Proarrhythmia has been noted in 2 to 3 percent of patients treated with intravenous
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ; it usually manifests as torsades de pointes, but ventricular fibrillation can occur [
         <a href="#rid4">
          4,6
         </a>
         ]. In a multicenter study in which 6 of 342 patients developed proarrhythmia, all had an exacerbating factor such as acute ischemia or an electrolyte imbalance [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Other cardiac side effects (bradycardia, asystole, heart failure, and shock), nausea, vomiting, and abnormal liver function tests occurred in 1 to 5 percent of patients each [
         <a href="#rid4">
          4,6
         </a>
         ].
        </p>
        <p>
         When given through peripheral intravenous lines,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         may cause local phlebitis [
         <a href="#rid33">
          33,34
         </a>
         ]. The risk of amiodarone-induced phlebitis increases with higher infusion rates and higher concentrations (eg, &gt;2 mg/mL). The risk of phlebitis can be reduced by using lower infusion rates (when possible), lower concentrations (&lt;2 mg/mL), or an in-line filter [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4967557">
         <span class="h2">
          Transition from IV to oral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The bioavailability of oral compared with intravenous
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ranges from 30 to 70 percent and is increased in the presence of food. Additionally, an increase in plasma levels may not be seen for four to five hours after the ingestion of oral amiodarone. We suggest the following approach to converting IV to oral amiodarone dosing:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have been on IV therapy for more than two weeks can be started on maintenance oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . The maintenance dose should be determined according to antiarrhythmic effect as assessed by patient tolerance as well as symptoms, Holter recordings, and/or programmed electrical stimulation. Whereas some patients can be controlled on lower doses (eg, 100 mg/day), others may require up to 400 to 600 mg/day for refractory arrythmias. The most common maintenance doses are between 100 and 400 mg/day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have been on IV therapy for one to two weeks can be started on an intermediate
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         dose of 400 to 800 mg/day. This should be continued until a total loading dose of 10 grams has been received, then the dose should be reduced to their maintenance dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have been on IV therapy for one week or less should probably receive the usual oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         loading dose of 400 to 1200 mg/day (typically in two divided doses). This should be continued until a total loading dose of 10 grams has been received, then the dose should be reduced to their maintenance dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Both oral and IV therapy can be given concurrently for a few days if there is a concern about gastrointestinal tract function.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4967564">
         <span class="h2">
          Dose adjustment
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is metabolized in the liver. The major metabolite is desethylamiodarone, which is active and has a longer elimination half-life than amiodarone [
         <a href="#rid1">
          1
         </a>
         ]. Dose reduction is probably necessary in patients with significant hepatic disease. By comparison, there is minimal elimination of both amiodarone and desethylamiodarone by the kidneys due both to the large volume of distribution and extensive protein binding; the latter effect also minimizes drug removal by dialysis. As a result, the dose of amiodarone does not have to be reduced in patients with renal disease or in patients undergoing dialysis.
        </p>
        <p class="headingAnchor" id="H4967572">
         <span class="h2">
          Drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is highly bound to plasma proteins (&gt;96 percent) and can alter the plasma concentration of other highly bound drugs. Interactions with other drugs, such as
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , must be considered. A few key drug interactions are discussed separately in UpToDate. Additionally, specific interactions of amiodarone with other medications may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring", section on 'Adverse drug interactions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5990258">
         <span class="h2">
          Use in children
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall safety and efficacy of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in children have not been fully established. Use of amiodarone in the treatment of tachyarrhythmias in children has been reported in several small series and one small clinical trial [
         <a href="#rid36">
          36
         </a>
         ]. Although amiodarone is effective for number of arrhythmias, its use in children is often limited by toxicities. Adverse events are common with IV amiodarone use in children and may be severe. Consultation with a pediatric cardiologist is advised. Severe adverse effects may include cardiovascular collapse, hypotension, bradycardia, and AV block. Nausea and vomiting are also common. ECG and blood pressure monitoring should be performed during administration of IV amiodarone.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         appears to be effective in the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supraventricular tachycardia (SVT) – In children with refractory SVT, IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is an option as second-line therapy for conversion to sinus rhythm. Use of IV amiodarone in this setting is generally limited to treatment of SVT that is refractory to other agents (
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         ), and oral amiodarone is a second-line therapy for the prevention of recurrent arrhythmia. In children with frequent or symptomatic SVT episodes, oral amiodarone is sometimes used for chronic management if there is a poor response to first- and second-line agents (eg, beta blockers,
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5782.html" rel="external">
          "Management of supraventricular tachycardia (SVT) in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wide QRS complex tachycardia – IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         has also been used, alone or in combination with other antiarrhythmic drugs, in infants and children with resistant, life-threatening ventricular tachyarrhythmias [
         <a href="#rid37">
          37,38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5758.html" rel="external">
          "Management and evaluation of wide QRS complex tachycardia in children", section on 'Shock-resistant tachyarrhythmia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Optimal dosing of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in children is not well established.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For oral therapy, dosing is based upon body weight or, in children less than one year of age, upon body surface area. The loading dose, which can be given in one or two divided doses per day, is 10 to 15 mg/kg per day or 600 to 800 mg/1.73 m
         <sup>
          2
         </sup>
         per day for 4 to 14 days or until adequate control of the arrhythmia is attained or prominent adverse effects occur. The dose should then be reduced to 5 mg/kg per day or 200 to 400 mg/1.73 m
         <sup>
          2
         </sup>
         per day once daily for several weeks. If the arrhythmia does not recur, the lowest effective dose should be used for maintenance. The usual minimal dose is 2.5 mg/kg per day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For IV therapy in critically ill children with tachyarrhythmias who have not responded to standard therapy, a variety of regimens have been used. We typically give a slow bolus infusion of 5 mg/kg (maximum dose 300 mg) IV over 20 to 60 minutes. If the patient does not convert to sinus rhythm, additional bolus doses of 1 to 5 mg/kg (up to a total of 15 mg/kg) can be given if there are no signs of toxicity (eg, hypotension, prolonged QT interval). This can be followed, if necessary, by a continuous infusion at a rate of 5 to 10 mcg/kg per minute.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3060430586">
         <span class="h2">
          Use in pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         has unique characteristics that mandate cautious use in pregnancy. The complications that can occur with the use of amiodarone during pregnancy are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypothyroidism or hyperthyroidism in the mother or fetus because of the iodine in
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal bradycardia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal QT interval prolongation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Premature labor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low birth weight
        </p>
        <p>
        </p>
        <p>
         In addition,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is found in fetal tissue and breast milk. For these reasons, the use of amiodarone in pregnancy should be reserved for maternal and fetal arrhythmias not responding to agents with known safety. Concomitant beta-blocker therapy should be avoided. Breast feeding is not recommended when the mother is taking amiodarone. (See
         <a class="medical medical_review" href="/z/d/html/13600.html" rel="external">
          "Supraventricular arrhythmias during pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15252.html" rel="external">
          "Maternal conduction disorders and bradycardia during pregnancy"
         </a>
         .)
        </p>
        <p>
         Neonates of mothers taking
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         should have complete thyroid function tests and developmental follow-up. (See
         <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">
          "Clinical features and detection of congenital hypothyroidism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6004536">
         <span class="h1">
          SIDE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         While
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         does have many potential benefits, side effects are a serious concern. Of greatest concern are potential toxicities involving the lungs, thyroid, liver, eyes, and skin  (
         <a class="graphic graphic_table graphicRef126072" href="/z/d/graphic/126072.html" rel="external">
          table 3
         </a>
         ). The potential side effects related to amiodarone use are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4236177160">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">
          "Society guideline links: Atrial fibrillation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">
          "Society guideline links: Ventricular arrhythmias"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/116931.html" rel="external">
          "Society guideline links: Supraventricular arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4967607">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electrocardiographic actions
         </strong>
         –
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         has various electrophysiologic properties that are favorable in the treatment of tachyarrhythmias. There are important differences in these properties between the oral and intravenous (IV) preparations. (See
         <a class="local">
          'Electrophysiologic properties'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         can slow the sinus heart rate, prolong the PR interval, widen the QRS complex, and prolong the QT interval on surface electrocardiogram. (See
         <a class="local">
          'Effects on the ECG'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of atrial arrythmias
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oral
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         – This can be used to treat most types of atrial arrhythmias but is used primarily to maintain normal sinus rhythm in patients with atrial fibrillation (AF). However, oral amiodarone is not FDA approved in the United States for rhythm control in AF, despite common usage for this indication. While there is no universally accepted dosing regimen  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ), oral loading doses of 400 to 1200 mg/day in divided doses (up to a total loading dose of 6 to 10 grams) can be used. The usual maintenance dose should be the lowest effective dose, which for AF is usually 200 mg daily but can sometimes be as low as 100 mg daily. (See
         <a class="local">
          'Oral amiodarone for the treatment of atrial arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IV
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         – This is primarily used for the treatment of atrial arrhythmias in two settings: restoration and maintenance of sinus rhythm in critically ill patients with hemodynamically unstable AF, and rate control in critically ill patients with AF with rapid ventricular response in whom the tachycardia is contributing to hemodynamic compromise. An initial IV loading dose of 150 mg is given over a minimum of 10 minutes  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ). More rapid infusion increases the risk of hypotension. The loading dose should be followed by a continuous infusion of 1 mg/minute for six hours and 0.5 mg/minute thereafter. (See
         <a class="local">
          'Intravenous amiodarone for the treatment of atrial arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of ventricular arrythmias
         </strong>
         –
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is useful in a variety of ventricular arrhythmias but is most commonly used for the secondary prevention of recurrent ventricular arrhythmias in patients, including patients with an implantable cardioverter-defibrillator (ICD) to reduce the frequency of ICD shocks. The recommended loading dose  (
         <a class="graphic graphic_table graphicRef117524" href="/z/d/graphic/117524.html" rel="external">
          table 4
         </a>
         ) for the prevention of ventricular arrhythmias is 400 to 1200 mg/day (usually in divided doses) for a total of 6 to 10 grams (except for secondary prevention of ICD shocks, when the loading dose is typically 8 to 10 grams). The maintenance dose should be determined according to antiarrhythmic effect as assessed by patient tolerance as well as symptoms, Holter recordings, and/or programmed electrical stimulation. Whereas some patients can be controlled on lower doses (eg, 100 mg/day), others may require up to 400 to 600 mg/day for refractory arrythmias. (See
         <a class="local">
          'Amiodarone for ventricular arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In the context of implantable cardioverter-defibrillators
         </strong>
         – Despite its effectiveness in reducing ventricular tachyarrhythmias,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         has been shown to be inferior to ICDs in reducing mortality in both primary and secondary prevention studies of patients at high risk for sudden cardiac death. Thus, the use of amiodarone in this setting should be reserved for patients who are candidates for an ICD but who cannot or refuse to have an ICD implanted. (See
         <a class="local">
          'Primary prevention of sudden cardiac death'
         </a>
         above and
         <a class="local">
          'Secondary prevention of sudden cardiac death'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transition from IV to oral dosing
         </strong>
         – The dosing of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         following conversion from IV to oral administration varies according to the duration of IV treatment prior to conversion. (See
         <a class="local">
          'Transition from IV to oral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug interactions and side effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         has the potential for numerous drug interactions and side effects  (
         <a class="graphic graphic_table graphicRef126072" href="/z/d/graphic/126072.html" rel="external">
          table 3
         </a>
         ) that require monitoring. (See
         <a class="local">
          'Drug interactions'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007; 4:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999; 100:2025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997; 127:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomes JA, Kang PS, Hariman RJ, et al. Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone. Am Heart J 1984; 107:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998; 81:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aiba T, Shimizu W, Inagaki M, et al. Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone. Pacing Clin Electrophysiol 2004; 27:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamiya K, Nishiyama A, Yasui K, et al. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 2001; 103:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lei LY, Chew DS, Lee W, et al. Pharmacological Cardioversion of Atrial Tachyarrhythmias Using Single High-Dose Oral Amiodarone: A Systematic Review and Meta-Analysis. Circ Arrhythm Electrophysiol 2021; 14:e010321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Um KJ, McIntyre WF, Mendoza PA, et al. Pre-treatment with antiarrhythmic drugs for elective electrical cardioversion of atrial fibrillation: a systematic review and network meta-analysis. Europace 2022; 24:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darkner S, Chen X, Hansen J, et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J 2014; 35:3356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohanty S, Di Biase L, Mohanty P, et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). Heart Rhythm 2015; 12:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997; 337:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet 2001; 357:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 89:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilleman DE, Spinler SA. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy 2002; 22:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chevalier P, Durand-Dubief A, Burri H, et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claro JC, Candia R, Rada G, et al. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev 2015; :CD008093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passman R, Subacius H, Ruo B, et al. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study. Arch Intern Med 2007; 167:2226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006; 295:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohnloser SH, Dorian P, Roberts R, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006; 114:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995; 122:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallik DM, Singer I, Meissner MD, et al. Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone. Am J Cardiol 2002; 90:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyce BA, Yee BH. Incidence and severity of phlebitis in patients receiving peripherally infused amiodarone. Crit Care Nurse 2012; 32:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton L, Ottoboni LK, Varady A, et al. Phlebitis in amiodarone administration: incidence, contributing factors, and clinical implications. Am J Crit Care 2013; 22:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oragano CA, Patton D, Moore Z. Phlebitis in Intravenous Amiodarone Administration: Incidence and Contributing Factors. Crit Care Nurse 2019; 39:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation 2005; 112:3470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996; 27:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figa FH, Gow RM, Hamilton RM, Freedom RM. Clinical efficacy and safety of intravenous Amiodarone in infants and children. Am J Cardiol 1994; 74:573.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 926 Version 48.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17765636" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A practical guide for clinicians who treat patients with amiodarone: 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10556230" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Evidence-based analysis of amiodarone efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17878423" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prescribing amiodarone: an evidence-based review of clinical indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9265430" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The role of intravenous amiodarone in the management of cardiac arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6695655" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7586313" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9514456" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15271008" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11238279" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24685669" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15872201" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Amiodarone versus sotalol for atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34802256" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pharmacological Cardioversion of Atrial Tachyarrhythmias Using Single High-Dose Oral Amiodarone: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35654763" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pre-treatment with antiarrhythmic drugs for elective electrical cardioversion of atrial fibrillation: a systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25182250" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25460855" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9400034" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11265951" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12767548" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11794432" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12535819" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9078198" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7539890" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26646017" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8960472" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10601507" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17998496" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10871966" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16403928" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16818810" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7702232" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Amiodarone: reevaluation of an old drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12398963" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22855076" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Incidence and severity of phlebitis in patients receiving peripherally infused amiodarone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24186821" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Phlebitis in amiodarone administration: incidence, contributing factors, and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30710042" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Phlebitis in Intravenous Amiodarone Administration: Incidence and Contributing Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16316969" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8609351" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8074040" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical efficacy and safety of intravenous Amiodarone in infants and children.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
